P&G Reports Thursday With the Street Already Tilted Long

Procter & Gamble arrives at its October 16 Q1 FY2027 earnings release in a notably uncontested setup: shorts have stayed put, options traders are barely hedged, and the stock has recovered cleanly over the past month.

The positioning picture has changed little since the October 12 stock report noted the same quiet. Short interest holds at 1.04% of the free float, flat across the past two weeks and well below the September spike that briefly reached 1.22% before unwinding. Borrow availability remains effectively unlimited, and cost to borrow is just 0.43%. The put/call ratio of 0.71 sits almost exactly in line with its 20-day average of 0.71, with a z-score near zero. There is no meaningful hedging pressure from options traders and no sign that short sellers are re-building positions into the print. The stock is up 5.3% over the past month to $153.04, with peers CL, KMB and CHD also posting solid weekly gains of 4.4%, 3.5% and 4.4% respectively, suggesting the move in PG is sector-wide rather than a stock-specific re-rating.

The analyst debate has tilted in a more constructive direction. Evercore ISI upgraded to Outperform on October 6, moving its target to $166, and that remains the freshest and most directional signal heading into Thursday. RBC Capital kept Outperform on the same day, trimming its target by just $1 to $166, which reads as confirmation rather than caution. The broader consensus remains Hold across 17 analysts, with 5 rated Outperform, meaning the upgrade from Evercore has not yet moved the crowd. Bulls emphasise volume recovery in Europe and Latin America, improving market-share trends, and forward earnings momentum that ranks in the 86th percentile on a 12-month basis. Bears return to the same structural problems: SK-II brand sales fell 30% in Greater China, US category growth slowed sharply in December, and both Argus and HSBC downgraded the stock in the months following the last print. The dividend score of 98 provides a floor for income investors, but the PE of roughly 21x and EV/EBITDA near 15x leave little margin for a volume miss.

The most notable recent insider activity cuts in two directions at once. On October 1, six executives including CEO Shailesh Jejurikar received stock awards, compensation grants rather than open-market purchases. Four days later, the CFO Andre Schulten, the Healthcare CEO Paul Gama, and the Chief Legal Officer each sold shares in the open market, with Schulten disposing of roughly $569,000 worth and none of the sales flagged as part of a pre-arranged 10b5-1 plan. The net insider position over 90 days is negative, at roughly -$7.9 million in value. The sales were modest relative to the company's scale, but their timing, one week before earnings, is worth noting.

The print on Thursday is less about whether P&G can defend its dividend and margins and more about whether volume trends in North America and China have genuinely turned, enough to justify the multiple and the constructive shift from Evercore that has already been priced into a stock trading 9% above where it closed after the last earnings release.